Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Closed 04-27 16:00:00 EDT

1.72

-0.07

-3.91%

盘后1.70

-0.02-1.16%

19:11 EDT

High1.81	Low1.68	Vol217.42K
Open1.81	D1 Closing1.79	Amplitude7.26%
Mkt Cap24.67M	Tradable Cap15.95M	Total Shares14.34M
T/O378.05K	T/O Rate2.35%	Tradable Shares9.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":1.72,"timestamp":1777320000000,"preClose":1.79,"halted":0,"volume":217420,"hourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.72,"latestTime":"19:11 EDT","volume":2096,"amount":3565.27,"timestamp":1777331519392,"change":-0.02,"changeRate":-0.011628,"amplitude":0.011628},"delay":0,"changeRate":-0.03910614525139668,"floatShares":9270600,"shares":14344000,"eps":-6.33,"marketStatus":"Closed","change":-0.07,"latestTime":"04-27 16:00:00 EDT","open":1.81,"high":1.81,"low":1.68,"amount":378052.85291200003,"amplitude":0.072626,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.33,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777363200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.79,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.79,"latestTime":"09:29 EDT","volume":5007,"amount":9284.551199399999,"timestamp":1777296599999,"change":0.02,"changeRate":0.011173,"amplitude":0.039106},"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.72,"latestTime":"19:11 EDT","volume":2096,"amount":3565.27,"timestamp":1777331519392,"change":-0.02,"changeRate":-0.011628,"amplitude":0.011628},"volumeRatio":1.392714,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/tweets","defaultTab":"tweets","newsList":[{"id":"2629494570","title":"Tempest Therapeutics provides update on development of TPST-2003","url":"https://stock-news.laohu8.com/highlight/detail?id=2629494570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629494570?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861021,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","BK4022","CAR","BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046835","title":"Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046835","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629046835?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:00","pubTimestamp":1776859200,"startTime":"0","endTime":"0","summary":"Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/Tempest-Announces-Key-Manufacturing-Milestone-for-TPST-2003-Dual-Targeting-CD19-BCMA-CAR-T.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAR","TPST","BK4022","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445581","title":"Press Release: Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445581?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:00","pubTimestamp":1776168000,"startTime":"0","endTime":"0","summary":"-- Adds dedicated business development leadership to support Tempest's. -- Will lead China outreach and cross-border partnership efforts. The appointment reflects Tempest's increasing emphasis on business development as a core strategic priority, including pursuing potential partnerships for its Phase 3-ready small molecule program, amezalpat, and advancing strategic collaborations across its CAR-T portfolio.Tempest continues to prioritize strategic partnerships for amezalpat, its Phase 3-ready small molecule program for hepatocellular carcinoma . Tempest previously announced clearance to proceed with a pivotal trial of amezalpat in China, building on alignment with the U.S. Food and Drug Administration  and European Medical Agency  on amezalpat's Phase 3 study design and positioning the program for potential global development. Tempest believes that these regulatory milestones also create opportunities for regional partnerships and cross-border collaborations.\"I am excited to join Tem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4139","CAR","TPST","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624706835","title":"Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624706835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624706835?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:13","pubTimestamp":1775124822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0H7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657057","title":"Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657057?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:13","pubTimestamp":1775124822,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624957046","title":"Tempest Therapeutics files to sell 2.78M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2624957046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624957046?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:11","pubTimestamp":1775124688,"startTime":"0","endTime":"0","summary":"06:07 EDT Tempest Therapeutics (TPST) files to sell 2.78M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-2-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-2-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","TPST","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623232294","title":"Tempest Therapeutics files to sell 8.27M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2623232294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623232294?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:05","pubTimestamp":1774908333,"startTime":"0","endTime":"0","summary":"18:00 EDT Tempest Therapeutics (TPST) files to sell 8.27M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-8-27m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-8-27m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TPST","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623247383","title":"Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2623247383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623247383?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:59","pubTimestamp":1774907974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I1E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346932","title":"BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346932","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346932?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:07","pubTimestamp":1774879655,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business UpdateMarch 30 (Reuters) - Tempest Therapeutics Inc TPST.O:TEMPEST REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES BUSI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623348929","title":"Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President","url":"https://stock-news.laohu8.com/highlight/detail?id=2623348929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623348929?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134816","title":"Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623134816?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623034894","title":"Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003","url":"https://stock-news.laohu8.com/highlight/detail?id=2623034894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623034894?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623834815","title":"Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623834815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623834815?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875600,"startTime":"0","endTime":"0","summary":"Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.Named Matt Angel, Ph.D., Chief Executive Officer & President. \"2025 was a transformative year for Tempest as we strengthened our pipeline with the strategic acquisition of a portfolio of next-generation CAR-T assets,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"The portfolio is already proving potentially fruitful as we reported encouraging early clinical data from our lead CAR-T program, TPST-2003, which is being tested in a Phase 1/2a trial in patients with relapsed or refractory multiple myeloma. The data, which suggests a favorable safety and efficacy profile for TPST-2003, reinforced our belief that this therapy has the potential to differentiate itself from currently approved CAR-T treatments and provide a meaningful option for patients who continue to face limited durable treatment options. We look forward to the potential initiation of a U.S. registrational s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","TPST","BK4161","BK4195","PFS","BK4230","BK4139","BK4022","CAR","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231089","title":"Tempest FY25 net loss narrows to $26.3 million; cash drops to $7.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231089?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:29","pubTimestamp":1774873760,"startTime":"0","endTime":"0","summary":"Tempest posted a net loss of $26 million, or $6.33 per share, for 2025.Cash and cash equivalents fell to $7.7 million at year-end.Research and development expenses dropped to $13 million due to re-prioritizing efforts toward exploring strategic alternatives.General and administrative expenses edged up to $14 million on one-time separation costs tied to employee terminations.Completed an all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, highlighting interim REDEEM-1 data showing a 100% complete response rate in six efficacy-evaluable rrMM patients, while targeting a U.S. IND submission and potential Phase 2b registrational study initiation for TPST-2003 in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL94CDWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008160","title":"Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008160","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008160?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:33","pubTimestamp":1774474386,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics CEO and President Matthew Angel reported an indirect purchase of 231,482 common shares at USD 2.16 per share.Following the reported transaction, he beneficially owned 4,837,070 common shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL465xJs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621712708","title":"Tempest Therapeutics announces USD 2 million private placement of 925,927 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621712708","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621712708?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267226,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics entered definitive agreements in a private placement to sell 925,927 common shares  at a combined purchase price of USD 2.16 per share.The transaction also includes Series A warrants and short-term Series B warrants for up to 925,927 shares each, with an exercise price of USD 2.16 per share.Gross proceeds are expected to be about USD 2 million, with potential additional gross proceeds of about USD 4 million if the warrants are fully exercised for cash.The securities were offered in an unregistered private placement under Section 4 of the Securities Act and/or Regulation D.H.C. Wainwright is acting as exclusive placement agent, and the company said it plans to use net proceeds for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7TtKf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2095319765.USD","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","SG9999014021.USD","BK4585","TPST","LU2210149790.SGD","NDAQ","IE00BN0W2T93.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708780","title":"Tempest Therapeutics Announces up to $6 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708780?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA36VQGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708708","title":"Press Release: Tempest Therapeutics Announces Up To $6 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708708","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708708?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.The securities described above are being offered in a private placement under Section 4 of the Securities Act of 1933, as amended , and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","TPST","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621477701","title":"Tempest Therapeutics Inc  expected to post a loss of 62 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621477701","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621477701?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:07","pubTimestamp":1774264027,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc  expected to post a loss of62cents a share - Earnings Preview Tempest Therapeutics Inc TPST.OQ TPST.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618442799","title":"Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support","url":"https://stock-news.laohu8.com/highlight/detail?id=2618442799","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618442799?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:01","pubTimestamp":1773230494,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support               Tempest selected Cincinnati Children’s Applied Gene and Cell Therapy ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbS1mGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","BK4585","SG9999014013.SGD","SG9999014005.SGD","TPST","BK4112","LU2210149790.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.0867},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.3993},{"period":"6month","weight":-0.8324},{"period":"1year","weight":-0.7776},{"period":"ytd","weight":-0.3763}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.122385},{"month":5,"riseRate":0.461538,"avgChangeRate":0.004949},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.113246},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.025247},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.054209},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}